A. Muhlethaler-Mottet

Dr. A. Muhlethaler-Mottet


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1994 in Science
Verified
Journal Article
Closed access
PDF file
VSViktor Steimle
Viktor Steimle
CSClaire-Anne Siegrist
Claire-Anne Siegrist
AMA. Muhlethaler-Mottet
A. Muhlethaler-Mottet
BLBarbara Lisowska-Grospierre
Barbara Lisowska-Grospierre
BMBernard Mach
Bernard Mach
Major histocompatibility complex (MHC) class II genes are expressed constitutively in only a few cell types, but they can be induced in the majority of them, in particular by interferon-γ (IFN-γ). The MHC class II transactivator gene CIITA is defective in a form of primary MHC class II deficiency. Here it is shown that CIITA expression is controlled and induced by IFN-γ. A functional CIITA gene is necessary for class II induction, and transfection of CIITA is sufficient to activate expression of MHC class II genes in class II-negative cells in the absence of IFN-γ. CIITA is therefore a general regulator of both inducible and constitutive MHC class II expression.

15 May 1997 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
AMA. Muhlethaler-Mottet
A. Muhlethaler-Mottet
LOLuc A. Otten
Luc A. Otten
VSViktor Steimle
Viktor Steimle
BMBernard Mach
Bernard Mach
The highly complex pattern of expression of major histocompatibility complex class II (MHC‐II) molecules determines both the immune repertoire during development and subsequently the triggering and the control of immune responses. These distinct functions result from cell type‐restricted expression, developmental control and either constitutive or inducible expression of MHC‐II genes. Yet, in these various situations, MHC‐II gene expression is always under the control of a unique transactivator, CIITA. Here we show that the CIITA gene is controlled by several distinct promoters, two of which direct specific constitutive expression in dendritic cells and B lymphocytes respectively, while another mediates γ‐interferon‐induced expression. Thus the cellular, temporal and functional diversity of MHC‐II expression is ultimately controlled by differential activation of different promoters of a single transactivator gene. This provides novel experimental tools to dissect compartment‐specific gain or loss of MHC‐II function in vivo .

1 February 1998 in Immunity
Verified
Journal Article
Closed access
AMA. Muhlethaler-Mottet
A. Muhlethaler-Mottet
WBWilma Di Berardino
Wilma Di Berardino
LOLuc A Otten
Luc A Otten
BMBernard Mach
Bernard Mach

1 May 2000 in Genes & Development
Verified
Journal Article
Closed access
PDF file
KMKrzysztof Masternak
Krzysztof Masternak
AMA. Muhlethaler-Mottet
A. Muhlethaler-Mottet
JVJean Villard
Jean Villard
MZMadeleine Zufferey
Madeleine Zufferey
VSViktor Steimle
Viktor Steimle
WRWalter Reith
Walter Reith
By virtue of its control over major histocompatibility complex class II (MHC-II) gene expression, CIITA represents a key molecule in the regulation of adaptive immune responses. It was first identified as a factor that is defective in MHC-II deficiency, a hereditary disease characterized by the absence of MHC-II expression. CIITA is a highly regulated transactivator that governs all spatial, temporal, and quantitative aspects of MHC-II expression. It has been proposed to act as a non-DNA-binding transcriptional coactivator, but evidence that it actually functions at the level of MHC-II promoters was lacking. By means of chromatin immunoprecipitation assays, we show here for the first time that CIITA is physically associated with MHC-II, as well asHLA–DM,Ii, MHC-I, andβ2mpromoters in vivo. To dissect the mechanism by which CIITA is recruited to the promoter, we have developed a DNA-dependent coimmunoprecipitation assay and a pull-down assay using immobilized promoter templates. We demonstrate that CIITA recruitment depends on multiple, synergistic protein–protein interactions with DNA-bound factors constituting the MHC-II enhanceosome. CIITA therefore represents a paradigm for a novel type of regulatory and gene-specific transcriptional cofactor.

4 May 2009 in Oncogene
Verified
Journal Article
Open access
PDF file
MFMarjorie Flahaut
Marjorie Flahaut
RMR Meier
R Meier
ACA Coulon
A Coulon
KNK A Nardou
K A Nardou
FNF K Niggli
F K Niggli
NGN Gross
N Gross
The development of chemoresistance represents a major obstacle in the successful treatment of cancers such as neuroblastoma (NB), a particularly aggressive childhood solid tumour. The mechanisms underlying the chemoresistant phenotype in NB were addressed by gene expression profiling of two doxorubicin (DoxR)-resistant vs sensitive parental cell lines. Not surprisingly, the MDR1 gene was included in the identified upregulated genes, although the highest overexpressed transcript in both cell lines was the frizzled-1 Wnt receptor (FZD1) gene, an essential component of the Wnt/β-catenin pathway. FZD1 upregulation in resistant variants was shown to mediate sustained activation of the Wnt/β-catenin pathway as revealed by nuclear β-catenin translocation and target genes transactivation. Interestingly, specific micro-adapted short hairpin RNA (shRNAmir)-mediated FZD1 silencing induced parallel strong decrease in the expression of MDR1, another β-catenin target gene, revealing a complex, Wnt/β-catenin-mediated implication of FZD1 in chemoresistance. The significant restoration of drug sensitivity in FZD1-silenced cells confirmed the FZD1-associated chemoresistance. RNA samples from 21 patient tumours (diagnosis and postchemotherapy), showed a highly significant FZD1 and/or MDR1 overexpression after treatment, underlining a role for FZD1-mediated Wnt/β-catenin pathway in clinical chemoresistance. Our data represent the first implication of the Wnt/β-catenin pathway in NB chemoresistance and identify potential new targets to treat aggressive and resistant NB.

13 August 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
Salomé Leibundgut-LandmannSalomé Leibundgut-Landmann
Salomé Leibundgut-Landmann
AMA. Muhlethaler-Mottet
A. Muhlethaler-Mottet
LBLuca Bernasconi
Luca Bernasconi
TSTobias Suter
Tobias Suter
JWJean-Marc Waldburger
Jean-Marc Waldburger
WRWalter Reith
Walter Reith
Cell surface expression of major histocompatibility complex class II (MHCII) molecules is increased during the maturation of dendritic cells (DCs). This enhances their ability to present antigen and activate naive CD4+ T cells. In contrast to increased cell surface MHCII expression, de novo biosynthesis of MHCII mRNA is turned off during DC maturation. We show here that this is due to a remarkably rapid reduction in the synthesis of class II transactivator (CIITA) mRNA and protein. This reduction in CIITA expression occurs in human monocyte-derived DCs and mouse bone marrow–derived DCs, and is triggered by a variety of different maturation stimuli, including lipopolysaccharide, tumor necrosis factor α, CD40 ligand, interferon α, and infection with Salmonella typhimurium or Sendai virus. It is also observed in vivo in splenic DCs in acute myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalitis. The arrest in CIITA expression is the result of a transcriptional inactivation of the MHC2TA gene. This is mediated by a global repression mechanism implicating histone deacetylation over a large domain spanning the entire MHC2TA regulatory region.